Benefit of high-dose idarubicin as induction therapy in acute myeloid leukemia: a prospective phase 2 study.
Mao YY, Cai HC, Shen KN, Chang L, Zhang L, Zhang Y, Feng J, Wang W, Yang C, Zhu TN, Duan MH, Zhou DB, Cao XX, Li J. Benefit of high-dose idarubicin as induction therapy in acute myeloid leukemia: a prospective phase 2 study. Ann Hematol. 2022 Apr; 101(4):831-836.